PNC-27 vs LL-37 — Peptide Comparison

PNC-27 vs LL-37 — Peptide Comparison PNC-27 vs LL-37 — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range PNC-27 1–2 mg LL-37 0.5–1.6 mg/mL (topical) Frequency Once daily Administration Subcutaneous injection Topical application (wound healing) Cycle Length 4-6 weeks 12+ weeks Onset Speed Rapid (hours to days) Moderate (1-2 weeks) Evidence Level Strong preclinical (extensive animal studies) Moderate human trials (Phase 1-2) Efficacy Cancer Cell Selectivity Rapid Action Broad Spectrum Wound Healing Fighting Infections Immune Boost Technical Data Molecular Formula C188H293N53O44S Molecular Weight 4031.73 g/mol Half-Life 2-4 hours (estimated from preclinical data) Bioavailability High when injected subcutaneously CAS Number 1159861-00-3 C205H340N60O53 4,493.26 Da Short systemic half-life (minutes) due to protease susceptibility; local tissue persistence at wound sites is longer due to binding to extracellular matrix components and lipid membranes Topical application achieves high local wound-bed concentrations; systemic bioavailability limited by rapid proteolytic degradation and serum protein binding; not intended for oral delivery 154947-66-7 Protocols starting 0.5 mg/mL gel Twice weekly 4 weeks Lowest dose in the LL-37 (ropocamptide) Phase I/IIa venous leg-ulcer trial and the most effective: ~6-fold faster healing and ~68% ulcer-area reduction vs placebo, applied to the wound twice weekly [4]. standard 1.6 mg/mL gel Mid dose in the same trial; ~3-fold improvement and ~50% area reduction vs placebo. The highest tested concentration (3.2 mg/mL) showed no benefit over placebo, so dose escalation above this is not supported [4]. Applications Solid Tumor Research PNC-27 has shown remarkable results against solid tumors in lab studies. It's been tested against breast, pancreatic, colon, and ovarian cancer cells—and in each case, it killed the cancer cells while the healthy cells next to them stayed perfectly fine. That's the holy grail of cancer research. Leukemia and Blood Cancer Studies In studies on acute myeloid leukemia (AML), PNC-27 wiped out cancer cells within just 4 hours. It works on several types of leukemia cells (U937, OCI-AML3, HL-60) by targeting a protein that only shows up on cancer cell surfaces. Normal blood cells? Completely unharmed. Cancer Stem Cell Targeting Here's where PNC-27 gets really interesting: it can kill cancer stem cells. These are the sneaky cells that often survive chemo and cause cancer to come back. PNC-27 has shown it can destroy CD44+ colon cancer stem cells, which is a big deal for preventing recurrence. Drug-Resistant Cancer Research When cancers stop responding to regular chemotherapy, researchers need new approaches. PNC-27 works through a completely different mechanism than traditional chemo drugs, so it may be effective against cancers that have become resistant to other treatments. Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers LL-37 is particularly well-suited for individuals focused on treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas) LL-37 is particularly well-suited for individuals focused on immune defense against antibiotic-resistant bacterial infections (mrsa, pseudomonas). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Anti-biofilm strategies for chronic wound infections and medical device-associated infections LL-37 is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and medical device-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Boosting innate immune defense in immunocompromised or aging individuals LL-37 is particularly well-suited for individuals focused on boosting innate immune defense in immunocompromised or aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach. Safety Profile Common Injection site redness Mild fatigue Localized warmth or tenderness Uncommon Headache Low-grade fever Serious Allergic reaction Local site irritation Transient stinging or burning Mild perilesional erythema Increased wound exudate Allergic contact reaction Hemolytic activity at systemic concentrations Research Status FDA Status Research compound Safety Overview Here's the really cool thing about PNC-27: in all the lab and animal studies so far, it ONLY attacks cancer cells. Normal, healthy cells are completely ignored because they don't have the protein (HDM-2) on their surface that PNC-27 targets. Animal studies using doses up to 40 mg/kg showed tumors shrinking or disappearing with zero damage to normal tissues. That said, it hasn't been tested in human clinical trials yet, so we're still learning. Contraindications xPregnancy or planning to become pregnant xCurrently breastfeeding xKnown allergy to peptide components xSevere immune system disorders without specialist guidance LL-37 is an endogenous cathelicidin antimicrobial peptide naturally produced by immune cells and epithelial tissues, conferring inherent biocompatibility and low toxicity at physiological concentrations. Synthetic LL-37 shows excellent safety in in vitro immune assays and animal models with no hepatotoxicity, nephrotoxicity, or genotoxicity at relevant doses. At elevated concentrations, the cationic amphipathic structure can cause hemolysis and cell membrane damage, but therapeutic doses are far below these thresholds. Injection site reactions are minimal in research applications. xKnown hypersensitivity to cathelicidin peptides or formulation components xActive hemolytic conditions — LL-37 demonstrates concentration-dependent hemolytic activity xPregnancy and breastfeeding — insufficient reproductive safety data from clinical trials xSevere renal impairment — peptide clearance may be altered Decision Guide Choose PNC-27 if... Cancer research protocols Oncology support research Targeting treatment-resistant cancers Cancer stem cell research Choose LL-37 if... Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas) Anti-biofilm strategies for chronic wound infections and medical device-associated infections Boosting innate immune defense in immunocompromised or aging individuals